ReviewNature biotechnology2004
Production of recombinant protein therapeutics in cultivated mammalian cells.
Review in Nature biotechnology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 510 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
510 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,992 citations in OpenAlex.
- Pooled it
- Review: A systematic review of virus-like particles of coronavirus: Assembly, generation, chimerism and their application in basic research and in the clinic.International journal of biological macromolecules · 2022Pooled it
- HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.The Journal of infectious diseases · 2025Trial
- Combining gene amplification with SEAP-reporter to achieve high expression of recombinant omicron XBB.1.5 spike protein.Protein expression and purification · 2027Article
- Photosynthetic production of glutamine through metabolic analysis-based engineering ofMetabolic engineering communications · 2026Article
- Metabolic Flux Analysis Reveals Cell Line-Specific Rewiring in CHO Cells Following TCA Cycle Intermediate Feeding for Bioprocess pH Control.Biotechnology and bioengineering · 2026Article
- A high-throughput co-culture CRISPR array for rapid fitness hypothesis testing and growth engineering in CHO cells.iScience · 2026Article
- Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Plant-based production and characterization of monoclonal antibodies targeting extracellular enveloped proteins of the Mpox Virus.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- UCOE-Mediated Transcriptional Stabilization Combined with EGFP-Based FACS Screening Enables Efficient Selection of High-Producing CHO Cells.Molecular biotechnology · 2026Article
- Industrial Bioreactor Technologies for Modern Biomanufacturing: Recent Applications in Microbial, Mammalian, and Plant-Based Systems.Molecular biotechnology · 2026Review
- Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Impact of N-1 phase media optimization as a bioprocess intensification strategy on fed-batch production.Bioprocess and biosystems engineering · 2026Article
- Editorial for Special Issue "Recombinant Proteins for Molecular Biology Research: Technologies and Applications".Current issues in molecular biology · 2026Article
- Development of an inducible stable producer cell line for rAAV production.Biochemical engineering journal · 2026Article
- Rapid quantitation of erythropoietin and identification of its glycans using membranes for capture and digestion.Talanta · 2026Article
- Efficient Construction of Recombinant CHO Cells for Stable Expression of Therapeutic Proteins Based on New Hotspot 'LOC'.Molecular biotechnology · 2026Article
- Workflows for stable cell line generation: Chemical transfection and viral transduction.Molecules and cells · 2026Article
- Engineered NLS-PBase system boosts stability and productivity in recombinant cell lines.Bioresources and bioprocessing · 2026Article
- Screening of quorum Sensing-Dependent strong promoters in Pseudomonas bijieensis 2P24 for metabolic optimization and Recombinant protein production.World journal of microbiology & biotechnology · 2026Article
450 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.